Dystonia 25 (DYT25) Cell Models for Research

Dystonia 25 (DYT25) is a rare form of primary dystonia, characterized by involuntary muscle contractions causing twisting and repetitive movements or abnormal postures. The exact prevalence is unknown, but it is estimated to affect a small fraction of the population. Onset is typically in adulthood, with a mean age of onset around 30 years. The condition is inherited in an autosomal dominant pattern with incomplete penetrance. There is no cure, and current treatments are symptomatic, including oral medications, botulinum toxin injections, and deep brain stimulation. The disease significantly impacts quality of life, leading to disability and social stigma. Research into the molecular mechanisms is crucial for developing targeted therapies.

DYT25 is an ideal model for studying the role of GNAL (G protein subunit alpha L) in neuronal function and signaling. The disease is monogenic, providing a clear genetic target. Public datasets, such as those from the 100,000 Genomes Project and ClinVar, provide genetic variants. Open questions include the precise molecular pathways affected by GNAL mutations and the development of effective therapies. Gene-edited cell models are essential for functional studies and drug screening.

• • DYT25 is not a cancer, but a neurological disorder. The primary pathway involves GNAL, which encodes the alpha subunit of the stimulatory G protein (Gs alpha). GNAL is highly expressed in the striatum, a brain region involved in motor control. Mutations in GNAL lead to reduced cAMP signaling, affecting dopamine and adenosine receptor signaling pathways. This disrupts the balance of direct and indirect pathways in the basal ganglia, leading to dystonia. Key steps:
• • GNAL mutations (e.g., missense, frameshift) lead to loss of function or dominant-negative effects.
• • Reduced Gs alpha activity decreases adenylyl cyclase activation, lowering cAMP levels.
• • Lower cAMP affects protein kinase A (PKA) activity and downstream targets, including DARPP-32.
• • Altered phosphorylation of ion channels and transcription factors leads to neuronal hyperexcitability and abnormal motor control.

Data from ClinVar and literature.

• • The primary deregulated network is the cAMP-PKA signaling pathway. Key nodes:
• • Gs alpha (GNAL) – stimulatory G protein
• • Adenylyl cyclase – converts ATP to cAMP
• • cAMP – second messenger
• • PKA – protein kinase A
• • DARPP-32 – dopamine- and cAMP-regulated phosphoprotein
• • Dopamine receptors (D1 and D2) – GPCRs that modulate cAMP
• • Adenosine A2A receptors – also couple to Gs
• • Other affected pathways include:
• • Calcium signaling: altered neuronal excitability
• • MAPK/ERK pathway: may be indirectly affected
• • Gene transcription: altered expression of immediate early genes

Organoids: 3D brain organoids derived from patient iPSCs can recapitulate neuronal development and function, providing a more physiologically relevant model for studying DYT25.

• • Animal models for DYT25 include:
• • GNAL knockout mice: exhibit dystonia-like movements and reduced striatal cAMP.
• • GNAL knock-in mice with patient-specific mutations: show motor deficits.
• • Viral vector-mediated gene transfer in rodents: to overexpress mutant GNAL.
• • Zebrafish models: used for drug screening.

These models are valuable for studying disease mechanisms and testing therapies.

• • Gene-edited cell models are crucial for studying DYT25. CRISPR-Cas9 technology allows the creation of isogenic cell lines with specific GNAL mutations. Examples:
• • GNAL knockout cell lines (e.g., in SH-SY5Y or HEK293) to study loss-of-function effects.
• • Knock-in cell lines with patient-specific point mutations (e.g., p.Arg220Trp) to model dominant-negative effects.
• • Reporter cell lines with fluorescent tags to monitor GNAL expression.

These models are commercially available from various sources, ensuring sequence verification and quality. They enable functional studies, drug screening, and target validation.

• • Gene-edited cell lines are used to validate the function of GNAL and other genes implicated in DYT25. For example:
• • Knockout of GNAL in neuronal cell lines reduces cAMP levels, confirming its role in signaling.
• • Knock-in of patient mutations can be compared to wild-type to assess dominant-negative effects.
• • CRISPR screens can identify genetic modifiers that rescue or exacerbate the phenotype.

• • Isogenic cell line pairs (wild-type vs. mutant) are used in high-throughput screening to identify compounds that restore normal signaling. For example:
• • Screening for small molecules that increase cAMP levels in GNAL mutant cells.
• • Testing drugs that target downstream effectors like PKA.
• • Modeling drug resistance by exposing cells to increasing concentrations of a compound and selecting for resistant clones.

CRISPR-based synthetic lethality screens can identify genes that are essential in GNAL mutant cells but not in wild-type cells. These genes could serve as therapeutic targets or biomarkers. Additionally, gene-edited cells can be used to identify secreted proteins or metabolites that reflect disease state.